• 1
    Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-infected women and prevention of perinatal HIV transmission. J Acquir Immune Defic Syndr 2002;29:48494.
  • 2
    Warszawski J, Tubiana R, Le Chenadec J, Blanche S, Teglas JP, Dollfus C, et al. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS 2008;22:28999.
  • 3
    Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000–2006. AIDS 2008;22:97381.
  • 4
    Hoffman RM, Black V, Technau K, van der Merwe KJ, Currier J, Coovadia A, et al. Effects of highly active antiretroviral therapy duration and regimen on risk for mother-to-child transmission of HIV in Johannesburg, South Africa. J Acquir Immune Defic Syndr 2010;54:3541.
  • 5
    Rouzioux C, Costagliola D, Burgard M, Blanche S, Mayaux MJ, Griscelli C, et al. Estimated timing of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission by use of a Markov model. The HIV Infection in Newborns French Collaborative Study Group. Am J Epidemiol 1995;142:13307.
  • 6
    Phuapradit W, Panburana P, Jaovisidha A, Vichitphun N, Kongsin P, Chantratita W, et al. Maternal viral load and vertical transmission of HIV-1 in mid-trimester gestation. AIDS 1999;13:192731.
  • 7
    Madger LS, Mofenson L, Paul ME, Zorrilla CD, Blattner WA, Tuomala RE, et al. Risk factors for in utero and intrapartum transmission of HIV. J Acquir Immune Defic Syndr 2005;38:8795.
  • 8
    British HIV Association. Management of HIV infection in pregnant women. 2008 []. Accessed 1 November 2011.
  • 9
    World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. 2010 []. Accessed 1 November 2011.
  • 10
    Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral pregnancy registry international interim report for 1 Jan 1989 – 31 January 2011. Wilmington, NC: Registry Coordinating Center. 2011 []. Accessed 1 November 2011.
  • 11
    Perinatal HIV Guidelines Working Group. Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. September 14, 2011; pp 1–207. []. Accessed November 1, 2011.
  • 12
    Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:11722.
  • 13
    Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, et al. Decay characteristics of HIV-infected compartments during combination therapy. Nature 1997;387:18891.
  • 14
    Wu H, Kuritzkes DR, McClernon DR, Kessler H, Connick E, Landay A, et al. Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationship to host factors, cellular restoration, and virologic end points. J Infect Dis 1999;179:799807.
  • 15
    Wright RL, Einstein F, Trentacoste S, Van Eerden P, Bebbington M, Irwin R, et al. Time to clinically significant viral suppression in HIV-infected pregnant women. Presented at 24th Annual Meeting of the Society of Maternal Fetal Medicine; 2004; New Orleans, Louisiana. Obstet Gynecol 2003;189:S102.
  • 16
    Euzrropean Collaborative Study. Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women. Clin Infect Dis 2007;44:164756.
  • 17
    Schalkwyk J, Chaworth-Musters T, Maan E, Gilgoff S, Tatum S, Burdge D, et al. Time to HIV suppression with HAART in pregnancy. Presented at the 14th Annual Meeting of the Conference on Retroviruses and Opportunistic Infections. 2007; Los Angeles, California. []. Accessed November 2011.
  • 18
    Bell C, Douglas M, Gilleece Y, Desmond N, Taylor GP. Early viral load reduction in pregnant women differs according to antiretroviral regimen. Presented at the 15th Annual Meeting of the Conference on Retroviruses and Opportunistic Infections. 2008; Boston, Massachusetts. []. Accessed November 2011.
  • 19
    Palacios R, Senise JF, Vaz MJ, Castelo A. Factors associated with virological response in women receiving highly-active antiretroviral prophylaxis for HIV mother-to-child transmission. Enferm Infecc Microbiol Clin 2008;26:4115.
  • 20
    Weinberg A, Harwood JE, McFarland EJ, Pappas J, Davies J, Kinzie K, et al. Kinetics and determining factors of the virologic response to antiretrovirals during pregnancy. Infect Dis Obstet Gynecol 2009;2009:621780. Epub 2010 Jan 10.
  • 21
    Briand N, Mandelbrot L, Blancher S, Tubiana R, Faye A, Dollfus C, et al. Previous antiretroviral therapy for prevention of mother-to-child transmission of HIV does not hamper the initial response to PI-based multitherapy during subsequent pregnancy. J Acquir Immune Defic Syndr 2001;57:12635.
  • 22
    Baroncelli S, Tamburrini E, Ravizza M, Dalzero S, Tibaldi C, Ferrazzi E, et al. Antiretroviral treatment in pregnancy: a six-year perspective on recent trends in prescription patterns, viral load suppression, and pregnancy outcomes. AIDS Patient Care STDS. 2009;23:51320.
  • 23
    American College of Obstetricians and Gynecologists. Scheduled cesarean delivery and the prevention of vertical transmission of HIV infection: ACOG committee opinion number 234 (replaces number 219). Int J Gynaecol Obstet 2001;73:27981.
  • 24
    Stanford University HIV Drug Resistance Database. []. Accessed April 2009.
  • 25
    Vittinghoff E, Glidden DV, Shiboski SC, McCulloch CE. Regression Methods in Biostatistics: Linear, Logistic, Survival, and Repeated Measures Models, 2nd edn. New York: Springer, 2012.
  • 26
    Lockman S, Hughes MD, McIntyre J, Zheng Y, Chipato T, Conradie F, et al. OCTANE A5208 Study Team. Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med 2010;363:1499509.
  • 27
    'Bryant A, Collingham J, Till M, Garcia P. Virologic and clinical outcomes in HIV-infected pregnant women: directly observed therapy can overcome barriers to care. Presented at the 11th Annual Meeting of the Conference on Retroviruses and Opportunistic Infections. 2004; San Francisco, California. []. Accessed November 2011.
  • 28
    McCabe CJ, Goldie SJ, Fisman DN. The cost-effectiveness of directly observed highly-active antiretroviral therapy in the third trimester in HIV-infected pregnant women. PLoS ONE 2010;5:e10154.
  • 29
    Goldie SJ, Paltiel AD, Weinstein MC, Losina E, Seage GR 3rd, Kimmel AD, et al. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med 2003;115:63241.
  • 30
    Bozzette SA, Gifford AL. The economic viability of antiretroviral adherence interventions. Am J Med 2003;115:6723.
  • 31
    Ciambrone D, Loewenthal HG, Bazerman LB, Zorilla C, Urbina B, Mitty JA. Adherence among women with HIV infection in Puerto Rico: the potential use of modified directly observed therapy (MDOT) among pregnant and postpartum women. Women Health 2006;44:6177.
  • 32
    Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recommen Rep 2006;55(RR-14):117.
  • 33
    Read JS, Newell MK. Efficacy and safety of cesarean delivery for prevention of mother-to-child transmission of HIV-1. Cochrane Database Syst Rev 2005;4:CD005479.
  • 34
    American College of Obstetricians and Gynecologists. Cesarean delivery on maternal request: ACOG committee opinion number 394. Obstet Gynecol 2007;110:15014.
  • 35
    Jamieson DJ, Read JS, Kourtis AP, Durant TM, Lampe MA, Dominguez KL. Cesarean delivery for HIV-infected women: recommendations and controversies. Am J Obstet Gynecol 2007;197(3 Suppl):S96100.